Studies have shown that oral administration of Akkermansia muciniphila can increase the recruitment of CCR9+CXCR3+CD4+ T lymphocytes to the tumor bed, thereby restoring the efficacy of PD-1 inhibitors in NSCLC patients (74). This evidence concerns the gene CCR9 and neoplasm.